Corporate Governance
MedSci Healthcare is led by our senior management team under the direction of our Board of Directors. The Board has adopted, and periodically reviews, policies and procedures to guide it in the discharge of its oversight responsibilities.
MedSci Healthcare
Dr. Zhang was appointed as a director of the company in November 2021 and was appointed as an executive director in April 2022. He has also served as the chairman of the board of directors since November 2021. Dr. Zhang is responsible for the overall strategic development, corporate governance, and management of the group. Previously, he served as the joint general manager of Shanghai Messe Medical from November 2012 to April 2015. Since October 2009, Dr. Zhang has been serving as an associate professor at Anhui University of Chinese Medicine, and since May 2021, he has been serving as the executive director of the World Federation of Chinese Medicine Societies. Since October 2017, Dr. Zhang has also been a member of the clinical trial contract research organization branch of the China Association for Quality Management of Medical and Pharmaceutical Products. Dr. Zhang obtained his bachelor's degree in acupuncture and his master's degree in integrated Chinese and Western medicine from Anhui College of Traditional Chinese Medicine (now known as Anhui University of Chinese Medicine) in July 1999 and July 2002, respectively. He also received his Ph.D. in natural science from the University of Chinese Academy of Sciences in China in March 2006.
执行董事，首席运营官，主要负责本集团的法律合规及战略合作事宜，于2020年6月起加入本公司，在这之前有近程先生拥有11年的咨询行业经验及5年的资讯科技公司经验，现为国际管理咨询协会会员及中国国家注册管理咨询师。程先生分别于2004年及2017年取得上海交通大学管理学学士学位及高级管理人员工商管理硕士学位。
Dr. Li has been serving as the director and general manager of Shanghai Miceutics since November 2012, and was appointed as the Co-CEO of Shanghai MedSci in March 2022. Prior to founding the group, Dr. Li served as a postdoctoral researcher at Florida State University and the University of Texas Southwestern Medical Center. Later, Dr. Li was appointed as an associate professor at Anhui University of Traditional Chinese Medicine in October 2009. Dr. Li obtained a bachelor's degree in traditional Chinese medicine and a master's degree in integrated traditional Chinese and Western medicine from Anhui University of Traditional Chinese Medicine in July 2000 and July 2003, respectively. He also received a PhD in biophysics from the University of Science and Technology of China in May 2006.
Appointed as a director of the group in November 2021, Mr. Wang was subsequently appointed as an executive director in April 2022. He also served as our Vice President since December 2021. Mr. Wang is responsible for the overall strategic planning, general management, and execution of our business operations. Since June 2016 and September 2020, he has also served as Vice President and Director of Shanghai MedSci. Mr. Wang obtained his Bachelor's degree in Clinical Medicine from China Medical University in July 2003.
MedSci Healthcare
王女士，40歲，擁有約12年股權投資經驗。自2012年3月起，彼一直擔任啟明創投（一間創投公司） 的執行董事。王女士亦於2008年7月至2010年5月擔任億康先達國際⼈⼒資源顧問股份有限公司（一間主要從事行政人員招募與領導力諮詢的實體） 的經理，並主要負責為中國金融機構提供高管招聘服務。於2006年9月至2008年7月期間，王女士擔任全球新聞機構法新社上海分社記者。王女士分別於2006年7月及2012年3月獲得復旦⼤學廣播電視新聞學士學位及中歐國際工商學院工商管理碩士學位。
Mr. Yan was appointed as our Director in November 2021 and re-designated as our non-executive Director in April 2022.
Prior to joining our Group, Mr. Yan served as a consultant at Roland Berger from December 2013 to May 2017, responsible for providing consultancy services for enterprise management. Concurrently, Mr. Yan has subsequently served as an investment associate and the investment director since June 2017 at Tencent Technology (Beijing) Co., Ltd. , a fellow subsidiary of Image Frame Investment (HK) Limited which is a shareholder of the Company, responsible for equity investment and related work.
MedSci Healthcare
Ms. Liu has been serving as an associate professor at the Antai College of Economics and Management, Shanghai Jiao Tong University since August 2001, and has also served as an independent director for Shanghai No. 1 Pharmacy (SHA: 600833), Shanghai Jielong Industry(SHA: 600836), Shanghai SafBon Water Service (SHE: 300262), Changjiang Investment Industrial(SHA: 600119), and she also served as an independent non-executive director of Glorious Property (HKG: 00845) and Shanghai Gench Education Group(HKG: 1525). The Board is of the view that Ms. Liu has the appropriate accounting or related financial management experience for the purpose of Rule 3.10(2) of the Listing Rules. Ms. Liu graduated from Shaanxi Institute of Finance), currently known as School of Economics and Finance of Xi’an Jiaotong University, in the PRC with a bachelor’s degree in finance in July 1986, and a master’s degree in economics in July 1989.
Mr. Yu was appointed as our independent non-executive Director with effect from the date of this Prospectus.He has extensive experience in branding strategy and management. Currently, Mr. Yu has served as a professor at Shanghai Jiao Tong Universitysince September 2005. Mr. Yu served as an independent director of Shandong Homey Aquatic Development(SHA:600467),, Shanghai Xujiahui Commercial (SHE:002561), Golden Home Living (SHA:603180) and Zoneco Group (SHE:002069), and he also served as an independent non-executive director of Noble Jewelry (HKG:00475) and Carpenter Tan(HKG:837). Mr. Yu received a Bachelor of Philosophy degree from Hangzhou University, China in July 1983, and a Master's degree in Management and a Doctoral degree in Management from Fudan University, China in July 1993 and July 1996, respectively.
Mr. Lau was appointed as our independent non-executive Director with effect from the date of this Prospectus. Prior to joining the Group, Mr. Lau served as the general manager at Baxter (China) Investments Co., Ltd from July 2002 to April 2009; as the president of China Biologic Products, Inc. from December 2010 to March 2012; as the chief operating officer at Eddingpharm Investment Co. Ltd. from March 2012 to February 2013; and as the chief executive officer at Amsino Medical Group from March 2013 to November 2014. Subsequently, Mr. Lau founded Shenzhen Tailai Biotechnology Co., Ltd. in July 2018 and has been the chairman of the board of directors since April 2020. Concurrently, Mr. Lau has served as an independent non-executive director of Solasia Pharma K.K.,(TYO: 4597), since December 2014; and as chairman of the board of directors and an independent director of Gland Pharma Ltd, (BOM: 543245), since June 2019. Mr. Lau obtained a bachelor’s degree in pharmaceutics from University of London in the United Kingdom.
English 
简体中文 
香港中文